Haemorrhagic complications associated with reduced alpha2-plasmin inhibitor during imatinib use in a patient with Philadelphia chromosome-positive acute lymphoblastic leukaemia. - Suppr | 超能文献

Haemorrhagic complications associated with reduced alpha2-plasmin inhibitor during imatinib use in a patient with Philadelphia chromosome-positive acute lymphoblastic leukaemia.

作者信息

Matsue Kosei, Aoki Takatoshi, Odawara Jun, Kimura Shun-ichi, Yamakura Masayuki, Takeuchi Masami

出版信息

Leuk Res. 2009 Jun;33(6):867-9. doi: 10.1016/j.leukres.2008.09.017. Epub 2008 Oct 31.

DOI:10.1016/j.leukres.2008.09.017

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Haemorrhagic complications associated with reduced alpha2-plasmin inhibitor during imatinib use in a patient with Philadelphia chromosome-positive acute lymphoblastic leukaemia.

Leuk Res. 2009 Jun;33(6):867-9. doi: 10.1016/j.leukres.2008.09.017. Epub 2008 Oct 31.

2

Use of dasatinib in the patient with Philadelphia chromosome-positive acute lymphoblastic leukaemia with resistance to imatinib and renal failure.

J Clin Pharm Ther. 2008 Jun;33(3):329-30. doi: 10.1111/j.1365-2710.2008.00916.x.

3

Bone marrow necrosis associated with the use of imatinib mesylate in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia.

Ann Hematol. 2006 Aug;85(8):542-4. doi: 10.1007/s00277-005-0071-3. Epub 2006 Mar 29.

4

Diminished alpha2-plasmin inhibitor activity associated with the use of imatinib mesylate in patients with Philadelphia chromosome-positive haematologic cancer.

Thromb Haemost. 2009 Jun;101(6):1170-1.

5

[New therapeutic strategy for Philadelphia chromosome-positive acute lymphoblastic leukemia].

Rinsho Ketsueki. 2006 Apr;47(4):294-302.

6

Anterior chamber infiltration in a patient with Ph+ acute lymphoblastic leukemia in remission with imatinib.

Am J Ophthalmol. 2005 Apr;139(4):723-4. doi: 10.1016/j.ajo.2004.09.075.

7

[Hypoprotidemia may explain imatinib intoxication in a patient with Philadelphia-positive acute lymphoblastic leukemia].

Therapie. 2013 Mar-Apr;68(2):125-7. doi: 10.2515/therapie/2013015. Epub 2013 Jun 18.

8

Impact of allogeneic haematopoietic stem cell transplantation in the outcome of Ph+ acute lymphoblastic leukaemia treated with an imatinib-containing regimen.

Br J Haematol. 2009 Sep;146(5):576-7. doi: 10.1111/j.1365-2141.2009.07800.x. Epub 2009 Jun 25.

9

Increasing the BCR-ABL expression levels and/or the occurrence of ABL point mutations does not always predict resistance to Imatinib Mesylate in BCR-ABL positive acute lymphoblastic leukemia.

Leuk Res. 2009 Jul;33(7):e73-4. doi: 10.1016/j.leukres.2008.11.009. Epub 2008 Dec 23.

10

Allo-hematopoietic cell transplantation for Ph chromosome-positive ALL: impact of imatinib on relapse and survival.

Bone Marrow Transplant. 2009 Jan;43(2):107-13. doi: 10.1038/bmt.2008.296. Epub 2008 Sep 8.

引用本文的文献

1

Chronic Subdural Hematoma Caused by Acute Myeloblastic Leukemia: A Case Report.

Front Neurol. 2022 Jul 12;13:911195. doi: 10.3389/fneur.2022.911195. eCollection 2022.

2

A case of subdural hematoma in patient with chronic myeloid leukemia treated with high-dose imatinib mesylate.

Korean J Hematol. 2010 Mar;45(1):73-5. doi: 10.5045/kjh.2010.45.1.73. Epub 2010 Mar 31.